Considering the correlation between the SFRP2 methylation status and BMI in CRC patients [14], together with the potential effect of neoadjuvant treatment on DNA methylation pattern; we propose that SFRP2 methylation could be associated with specific clinical outcome of CRC patients and this relationship could be affected by BMI or treatment. The gene discussed is SFRP2; the disease is colorectal carcinoma.